MX2024011382A - Composiciones y metodos farmaceuticos de esfingomielinasa acida humana recombinante. - Google Patents

Composiciones y metodos farmaceuticos de esfingomielinasa acida humana recombinante.

Info

Publication number
MX2024011382A
MX2024011382A MX2024011382A MX2024011382A MX2024011382A MX 2024011382 A MX2024011382 A MX 2024011382A MX 2024011382 A MX2024011382 A MX 2024011382A MX 2024011382 A MX2024011382 A MX 2024011382A MX 2024011382 A MX2024011382 A MX 2024011382A
Authority
MX
Mexico
Prior art keywords
methods
compositions
rasm
acid sphingomyelinase
recombinant human
Prior art date
Application number
MX2024011382A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Brower
Xiaoying Jin
Thomas M Wasylenko
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2024011382A publication Critical patent/MX2024011382A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024011382A 2022-03-18 2023-03-17 Composiciones y metodos farmaceuticos de esfingomielinasa acida humana recombinante. MX2024011382A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263321636P 2022-03-18 2022-03-18
PCT/US2023/064657 WO2023178325A1 (en) 2022-03-18 2023-03-17 Pharmaceutical recombinant human acid sphingomyelinase compositions and methods

Publications (1)

Publication Number Publication Date
MX2024011382A true MX2024011382A (es) 2024-09-23

Family

ID=86051983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011382A MX2024011382A (es) 2022-03-18 2023-03-17 Composiciones y metodos farmaceuticos de esfingomielinasa acida humana recombinante.

Country Status (12)

Country Link
US (1) US20230365946A1 (https=)
EP (1) EP4493684A1 (https=)
JP (1) JP2025509722A (https=)
KR (1) KR20240156645A (https=)
CN (1) CN119365593A (https=)
AR (1) AR128825A1 (https=)
AU (1) AU2023235321A1 (https=)
CA (1) CA3254814A1 (https=)
IL (1) IL315655A (https=)
MX (1) MX2024011382A (https=)
TW (1) TW202403043A (https=)
WO (1) WO2023178325A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4594462A1 (en) 2022-09-28 2025-08-06 Genzyme Corporation Systems and devices for producing biological products and methods of using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US20020137173A1 (en) * 2001-02-05 2002-09-26 Dae-Kyong Kim Membrane-associated sphingomyelinase derived from bovine brain, isolation method therefor and anti-sphingomyelinase monoclonal anitibody
US7527956B2 (en) * 2003-06-12 2009-05-05 Genzyme Corporation Modified human acid sphingomyelinase having increased activity, and methods for making the same
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
KR20100103595A (ko) 2008-01-18 2010-09-27 에프. 호프만-라 로슈 아게 비-글라이코실화된 단백질의 정제
RU2012151132A (ru) 2010-05-19 2014-06-27 Ф. Хоффманн-Ля Рош Аг Хроматография с гиброфобным взаимодействием
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
EP2997036B1 (en) 2013-05-15 2021-03-03 Medimmune Limited Purification of recombinantly produced polypeptides
DK3728287T3 (da) 2017-12-19 2024-06-10 CSL Behring Lengnau AG Proteinoprensning og virusinaktivering med alkylglycosider
PY1939780A (es) 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida

Also Published As

Publication number Publication date
JP2025509722A (ja) 2025-04-11
TW202403043A (zh) 2024-01-16
WO2023178325A1 (en) 2023-09-21
IL315655A (en) 2024-11-01
KR20240156645A (ko) 2024-10-30
US20230365946A1 (en) 2023-11-16
AR128825A1 (es) 2024-06-19
CA3254814A1 (en) 2023-09-21
AU2023235321A1 (en) 2024-10-31
CN119365593A (zh) 2025-01-24
EP4493684A1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
ZA200107110B (en) Medicament for treating diabetes.
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
WO2020198695A8 (en) Compositions, devices and methods for factor vii therapy
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE60036490D1 (de) Zusammensetzung zur behandlung von prostatakrebs
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
DE60207383D1 (de) Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen
AP1760A (en) Platinum derivative pharmaceutical formulations.
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
YU12700A (sh) Primena polipeptidnog analoga pertida srodnoga paratireoidnom hormonu i njegovih soli za proizvodnju medikamenata za lečenje preloma kostiju
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
ES8602118A1 (es) Un procedimiento para preparar un conjugado de proteina fibrinoliticamente activa
CL2022001655A1 (es) Variantes diseñadas de la alfa-glucosidasa ácida.
MX2024011382A (es) Composiciones y metodos farmaceuticos de esfingomielinasa acida humana recombinante.
ATE541583T1 (de) Enzym-enthaltendes präparat, verfahren zur herstellung und verwendung
WO2021173928A3 (en) Human alpha-galactosidase variants
TNSN04235A1 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
NZ515531A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
MX2025002176A (es) Inhibidores de tyk2 y usos de los mismos
NO20003888L (no) Anti-enzympreparater omfattende etylendiamindiravsyre
TR200101980T2 (tr) Arilalkanoil türevleri, bunların preparasyon işlemleri
MXPA02011162A (es) Proteina cln2 recombinante de humano y metodos para su reduccion y uso.